GEN News Highlights

Waters Boosts Lipidomics Research Offerings through Deal with Premier Biosoft

(Page
1
of
1)

Waters will market Premier Biosoft's SimLipid® informatics platform, with the goal of augmenting company lipidomics research capabilities. Current offerings include the Acquity UPLC® liquid chromatography system and the high-resolution Synapt® and Xevo® mass spectrometers.

SimLipid is an automatic analysis software that can augment data generated by Waters’ UPLC—HDMSe (ion mobility—mass spectrometry) system by performing an exact mass precursor ion search to generate a list of lipid candidates. Those candidates are then ranked by comparing diagnostic product ions observed in the high energy HDMSe data and structure-specific in silico fragment ions from the SimLipid database.

SimLipid generates portable reports and images in the XLS, CSV, HTML, JPEG, and PNG file formats to facilitate information sharing. Waters says that each structure is mined for its associated class, reaction, pathway, and enzyme to minimize costly and time-consuming manual annotation by scientists.

Waters says its mass spectrometer technology provides greater levels of specificity and class separation to lipid analysis, including the separation of isobaric and isomeric lipid species.

The companies signed a nonexclusive co-marketing and reselling agreement that marks the second accord between the companies in over a year. In May 2010, Waters and Premier Biosoft inked a deal to co-market the SimGlycan® software with Waters mass spectrometry solutions for glycan and glycopeptide analysis. As part of that deal Premier Biosoft agreed to market its software to customers analyzing glycans and glycopeptides on both the Waters Synapt and Xevo mass spec platforms.

Under the new agreement, Waters will continue to sell its UPLC and mass spectrometers for lipid analysis, while Premier Biosoft will market its characterization tool to Waters customers analyzing lipid data.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.